Economy/Home · Economy

[U.S. Stock!Star] uniQure's Huntington's Gene Therapy AMT-130 Slows Disease Progression by 80% at 3 Years in Clinical Trial... Falls 47% in Premarket After 4-Year Endpoint Misses Statistical Significance

uniQure (NASDAQ: QURE), a biotech company listed on the U.S. Nasdaq, has released additional clinical results for its Huntington's disease gene therapy candidate AMT-130. At the three-year (36-month) mark, disease progression slowed by up to 80%, while at four years (48 months) of follow-up, the key

Oseong Kwon
Staff Reporter
11 min read
[U.S. Stock!Star] uniQure's Huntington's Gene Therapy AMT-130 Slows Disease Progression by 80% at 3 Years in Clinical Trial... Falls 47% in Premarket After 4-Year Endpoint Misses Statistical Significance
CBC News

uniQure (NASDAQ: QURE), a biotech company listed on the U.S. Nasdaq, has released additional clinical results for its Huntington's disease gene therapy candidate AMT-130. At the three-year (36-month) mark, disease progression slowed by up to 80%, while at four years (48 months) of follow-up, the key assessment measures failed to achieve statistical significance. On this news, uniQure's stock is plunging in premarket trading.

■ 36-Month Data: 80% Slowing of Progression by cUHDRS

On the 29th (local time), uniQure announced additional Phase 1/2 data for efepriersen enilparvovec (AMT-130), its Huntington's disease gene therapy candidate. The release included 36-month and 48-month follow-up results for high-dose and low-dose patients obtained through June 30, 2026.

In the 36-month analysis of 15 high-dose patients, the rate of disease progression measured by the composite Unified Huntington's Disease Rating Scale (cUHDRS) was 80% slower than the external control arm, with a nominal p-value of 0.005. On the Total Functional Capacity (TFC) scale, which evaluates patients' ability to perform activities of daily living, disease progression was 67% slower than the external control arm, with a nominal p-value of 0.011. Three additional high-dose patients were included in this 36-month analysis compared to the previous announcement.

■ 48-Month Timepoint: cUHDRS Fails to Achieve Significance

In contrast, at the 48-month timepoint, the treatment effect appeared relatively diminished on some measures. In an analysis of 12 high-dose patients, disease progression by cUHDRS was 44% slower than the external control arm, but with a p-value of 0.144, it did not achieve statistical significance. However, by TFC, disease progression was 61% slower, with a nominal p-value of 0.008.

■ 53% Missing Data Rate in External Control Arm: "Possible Impact on Effect Evaluation"

uniQure explained that the increased rate of missing data in the external control arm during long-term follow-up may have affected the evaluation of the treatment effect. In fact, at 48 months, the missing data rate in the updated external control arm reached 53%. The company analyzed that because patients who dropped out of follow-up had relatively faster disease progression, the degree of disease progression in the external control arm may have been underestimated.

In a post-hoc sensitivity analysis using the existing external control arm, disease progression at 48 months was slowed by 53.5% by cUHDRS and 68.3% by TFC. However, post-hoc analysis results need to be interpreted separately from the pre-specified primary assessment results.

■ High Dose vs. Low Dose: "Consistent with Dose-Dependent Effect"

Differences in treatment effect by dose were also confirmed. At 48 months, comparing 12 high-dose patients and 12 low-dose patients, relatively favorable outcomes were observed in the high-dose group on both cUHDRS and TFC. uniQure explained that this difference is consistent with a dose-dependent treatment effect.

■ Safety: "Manageable Tolerability"... One Additional Suicide Death Reported

In terms of safety, overall manageable tolerability was observed. However, treatment-related serious adverse events associated with central nervous system inflammation had previously been reported in five high-dose patients, and according to the company, all cases recovered. In addition, one additional case was reported in which a low-dose patient died by suicide approximately five years after treatment, which the clinical trial investigator assessed as unrelated to the therapy.

■ What Is AMT-130: Designed to Suppress Huntingtin Gene Expression

AMT-130 is a gene therapy candidate designed to suppress the expression of the huntingtin gene. It is being developed as a one-time administration delivered directly into the striatum of the patient's brain. Currently, there are no approved therapies that delay the onset of Huntington's disease or slow disease progression itself.

According to uniQure, the U.S. Food and Drug Administration (FDA), at a meeting in June, indicated that 36-month data from 12 high-dose patients could be used as the primary basis for an accelerated approval application, and the company submitted a Biologics License Application (BLA) on that basis. However, the additional clinical data newly disclosed this time were not included in the existing approval application materials.

■ Focus Shifts to Regulators' Evaluation of Long-Term Data

Going forward, attention is expected to focus on regulatory authorities' evaluation of the long-term follow-up data. While the disease progression inhibition effect shown in the 36-month analysis and the 48-month TFC results present positive signals, the 48-month cUHDRS result failed to achieve statistical significance, making further verification critical.

Meanwhile, as of 10:12 p.m. on the 29th, Korea time, uniQure shares were trading at $20.69 in the premarket, down $18.42 (47.0%) from the previous regular session close. With stock price volatility expanding following the release of the long-term clinical results, attention is focused on the company's additional explanations and the progress of the FDA approval review.

['U.S. Stock!Star' is overseas stock content, including U.S. stocks, provided by CBC News, and we will strive to provide readers with a broad range of information going forward. All investments are made at each individual's own discretion, and the final responsibility lies with the investor.]

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.